Professor Evandro de Azambuja from Institut Jules Bordet and Dr Kevin Punie...
KEYNOTE-522, a widely recognized phase 3 trial, has led to a paradigm shift in...
The review article discussed systematically assesses the impact of ADCs in BC...
Capecitabine constitutes a pivotal therapeutic agent for breast cancer...
At ASCO 2023, data were presented from a meta-analysis investigating ovarian...
The TROPiCS-02 trial represents an international, open-label, phase 3...
The DATA trial systematically explored the efficacy of extended adjuvant...
The IMpassion 031 trial explored the potential benefits of neoadjuvant and...
The SOFT trial investigates the impact of adding ovarian function suppression...
The PALMIRA trial, a phase 2 open-label randomised study, sought answers to the...